By influencing gut microbiota composition, GLP-1 agonists enhance gut barrier integrity, reducing permeability and systemic inflammation, which are hallmarks of metabolic dysfunction in obesity. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.